AZN vs NVS: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
AZN (AstraZeneca) and NVS (Novartis AG) share investment themes but are different businesses. The right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme.
AZN vs NVS: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AZN | NVS | What it tells you |
|---|---|---|---|
| Market cap | $289.90B | $304.96B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 16.52 | 16.25 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 26.44 | 30.81 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.17 | 0.46 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 57% of range | 81% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.60 | 8.19 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AZN and NVS affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AZN and NVS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AZN and NVS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does AstraZeneca (AZN) do?
AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. It develops and sells prescription medicines across four main areas: oncology (its biggest engine), cardiovascular-renal-metabolism, respiratory and immunology, and rare disease through Alexion, which it acquired in 2021. Flagship products include the cancer drugs Tagrisso, Imfinzi, Calquence, Lynparza (partnered with Merck) and Enhertu (partnered with Daiichi Sankyo), plus the diabetes and heart-failure drug Farxiga and rare-disease therapies like Ultomiris and Soliris. In 2025 the company reported total revenue of about $58.7 billion, up roughly 9%, and it has set a public ambition to grow that to $80 billion by 2030, with about half expected to come from the United States.
What does Novartis AG (NVS) do?
Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025. Revenue was about $56.7 billion in 2025, roughly 10% above 2024, and trailing twelve-month revenue is at about the same level with net income near $12.8 billion.
AZN vs NVS: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- AZN drivers: Oncology franchise and the $80 billion ambition; Deep late-stage pipeline.
- NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. For NVS, the dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed.
AZN or NVS: which should you pick?
AZN vs NVS: the full fundamentals
AZN. AstraZeneca trades at about 25 times trailing reported earnings but about 14.6 times forward earnings, a gap that reflects heavy amortisation and one-off charges in reported profit and consensus for 2026 core EPS near $10.05 rising to about $11.34 in 2027. After falling about 9.5% in 2026, the forward multiple sits near the low end of where a growth-oriented large-cap pharma usually trades, so the valuation now reflects more caution about the 2032 patent cliff than enthusiasm for the $80 billion 2030 goal. Q3 2026 results arrive October 30, with consensus revenue near $16.0 billion. Figures are approximate and tied to the asOf date; confirm live numbers before acting.
NVS. At about $151, NVS trades near 23 times trailing earnings but only about 15 times forward estimates, a gap that reflects reported profit depressed by the Entresto cliff and an expected rebound to about $9.80 of EPS in 2027. The analyst mean target of roughly $155 sits close to the current price, so the October 27 third-quarter report and how fast the growth brands keep absorbing the generic erosion matter more than any single trailing figure. Figures are approximate and tied to the asOf date; verify live numbers before acting.
Headline figures (approximate, October 2026): AZN shows revenue (ttm) About $61.4 billion; Q2 2026 revenue about $15.4 billion, up roughly 6% year over year, net income (ttm) About $10.5 billion, a net margin near 17%, with gross margin near 82%, eps Q2 2026 EPS $1.32 vs about $1.25 expected; trailing reported EPS about $6.69, p/e About 25x trailing reported earnings, about 14.6x forward; NVS shows revenue (ttm) ~$56.7B; Q2 2026 revenue ~$14.95B, up ~1% year over year, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix offsetting Entresto's generic decline, margins (ttm) ~75% gross, ~35% operating, ~22.5% net, net income (ttm) ~$12.8B.
The bottom line: AZN vs NVS
AZN and NVS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AZN and NVS exposure against your real portfolio. It is not an investment adviser.
Wondering how AZN or NVS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in AstraZeneca with AI
Connect the broker you already use and ask Walnut's AI how AZN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between AZN and NVS?
+
AstraZeneca is one of the world's largest biopharmaceutical companies, headquartered in Cambridge, England, with deep Anglo-Swedish roots. Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AZN or NVS the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AZN or NVS?
+
On forward P/E (as of November 2026), AZN trades at 16.52x and NVS at 16.25x, so NVS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AZN and NVS?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AZN vs NVS?
+
AZN: The dominant risk is the patent cliff: from around 2032, Tagrisso, Imfinzi and Calquence are expected to begin losing exclusivity, a headwind analysts have sized at more than $20 billion, so the whole thesis hinges on the pipeline replacing that revenue in time. Generic and biosimilar erosion is already visible, with first generics to Farxiga cleared in 2026. Pipeline risk is constant, since late-stage trial failures such as a disappointing AVANZAR result can erase billions in expected value quickly. China, about a tenth of revenue, carries added uncertainty after the company's former China head was indicted in a compliance case that drew investor lawsuits. Drug pricing policy, US tariffs and currency swings add further volatility, and the balance sheet carries about $32 billion of debt against about $5 billion of cash. As a large-cap pharma the stock can still fall sharply on a single disappointing readout or regulatory decision, as its roughly 22% slide from the 52-week high shows. NVS: The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. Analysts expect 2026 EPS to slip about 2% before rebounding in 2027, and reported earnings growth was about -17% year over year in the latest quarter. Pipeline risk is structural because late-stage trials can fail and regulators can reject or delay approvals, turning expected future revenue into a write-off. Large acquisitions such as Avidity add integration and financing risk and raised debt, which stood at about $49 billion against about $7.6 billion of cash in mid-2026. US drug-pricing policy, potential pharmaceutical tariffs, and pricing pressure are outside the company's control and could compress margins. Because NVS is a Swiss ADR, US investors also carry dollar-versus-Swiss-franc currency risk, and Swiss dividend withholding tax reduces net income for some holders. Concentration in a handful of growth drugs means a single clinical or commercial setback can move the stock.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AZN or NVS; figures are approximate and dated (as of November 2026). Verify current data before investing.